BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key
Will activist investors succeed in unlocking Bristol-Myers Squibb's shareholder value - or instead orchestrate a takeover worth more than $100bn?
You may also be interested in...
The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.